Medtronic (NYSE:MDT) announced today that the FDA approved its Vanta recharge-free implantable neurostimulator (INS).
Fridley, Minn.-based Medtronic touts the Vanta INS as having a device life of up to 11 years, which stands as more than twice the device life of competitive primary cell devices, according to a news release.
Additionally, Vanta uses Medtronic’s proprietary AdaptiveStim technology that adapts to the patient’s movement or body position through a built-in accelerometer. The platform can automatically adjust stimulation to maintain each patient’s optimal dose.
Vanta represents a 10% increase in longevity when compared to Medtronic’s previous generation of recharge-free device, the PrimeAdvanced. Its design marks a 20% decrease in size compared to PrimeAdvanced, with a more rounded, ergonomic contouring for enhanced comfort, the medtech giant said.
The platform can access Medtronic’s proprietary Snapshot data insights solution to allow clinicians to access objective reports of patient activity levels.
“We are committed to delivering innovative solutions that meets the needs of every patient,” Medtronic VP & GM of pain therapies within the neuromodulation business Charlie Covert said in the release. “For those who prefer or require a recharge-free device, I believe the Vanta neurostimulator offers the best hardware and features available today. We are pleased to offer this solution, which is now part of the strongest and broadest overall portfolio in this market.”